| Oct 22 |
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
|
| Oct 21 |
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year
|
| Oct 15 |
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
|
| Sep 23 |
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
|
| Sep 23 |
XOMA Royalty Declares Quarterly Preferred Stock Dividends
|
| Sep 10 |
High Growth Tech Stocks In The United States To Watch
|
| Sep 4 |
XOMA Royalty to Present at Upcoming Investor Conferences in September
|
| Aug 13 |
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 13 |
XOMA Royalty: Q2 Earnings Snapshot
|
| Aug 13 |
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
|
